Physician profile

Ronald E Strobel

Cardiovascular Disease · Englewood, NJ

NPI 1952360240

$9,236.42

in general payments reported to CMS, 2019-2025

39 companies · $1,178 in 2025

The $1,178 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$4,085.25
Education$28.11

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $1,526.67 2019-2025
Janssen Pharmaceuticals, INC $1,288.83 2019-2024 Xarelto
Amgen INC. $1,069.24 2019-2025 Repatha, Repatha
Astrazeneca Pharmaceuticals Lp $873.58 2019-2025 Farxiga, Wainua
Medtronic, INC. $668.39 2021-2025 Micra, Aurora Ev-Icd Mri Surescan
Amarin Pharma, INC. $533.33 2019-2023
Merck Sharp & Dohme LLC $404.20 2021-2025 Verquvo
Boehringer Ingelheim Pharmaceuticals, INC. $377.93 2019-2025 Jardiance
Baxter Healthcare $289.88 2023-2025 Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor
Sanofi-Aventis U.S. LLC $257.91 2019-2021
Pfizer INC. $200.37 2020-2025
Medtronic Vascular, INC. $196.05 2020
Esperion Therapeutics, INC. $156.72 2021-2024 Nexletol
Regeneron Healthcare Solutions, INC. $149.71 2019-2022
Preventice Services, LLC $132.33 2019
Show all 39 companies
CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $126.32 2021-2025 Wegovy, Ozempic, Rybelsus
Edwards Lifesciences Corporation $114.84 2019
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $83.25 2021-2023 Lifevest
Irhythm Technologies, INC. $82.26 2020-2024 Zio Xt Patch, Zio Monitor
Bridgebio Pharma, INC. $69.87 2025 Attruby
Medicomp INC $65.73 2024-2025 Telepatch Cardiac Monitor
Cvrx, INC. $58.54 2024 Barostim Neo System
Abiomed $57.58 2024-2025 Impella
E.R. Squibb & Sons, L.L.C. $56.54 2019-2025 Camzyos
Kiniksa Pharmaceuticals, Ltd. $44.34 2023 Arcalyst
Boston Scientific Corporation $43.92 2022-2024 Zoom Wireless Transmitter
Atricure, INC. $42.76 2023
Lundbeck LLC $36.69 2019-2021
Lilly USA, LLC $34.82 2024-2025 Zepbound, Mounjaro
Alnylam Pharmaceuticals INC. $31.71 2025 Amvuttra
Impulse Dynamics (USA) INC. $27.32 2022
Abbott Laboratories $27.02 2021
Vivaquant INC, Dba Rhythm Express $26.94 2025 Rhythm Express
Portola Pharmaceuticals, LLC $14.48 2019
Bayer Healthcare Pharmaceuticals INC. $14.23 2025
Lexicon Pharmaceuticals, INC. $14.04 2024
Heartflow, INC. $13.30 2023 Ffrct
Ani Pharmaceuticals, INC. $13.11 2024 Purified Cortrophin Gel
Allergan, INC. $11.67 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ronald E Strobel

$9,236.42

in general payments reported 2019-2025

Years
2019-2025
Top company
Novartis Pharmaceuticals Corporation
Context
The $1,178 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/361624/ronald-e-strobel

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.